<DOC>
	<DOCNO>NCT00111436</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability long-term administration etanercept adult psoriasis participate previous etanercept psoriasis study . This study also evaluate maintenance efficacy etanercept adult psoriasis participate previous etanercept psoriasis study . All subject enrol study receive 50 mg weekly twice weekly ( qualified week 12 ) subcutaneous injection least 48 week 72 week .</brief_summary>
	<brief_title>Evaluating Safety Etanercept Treatment Psoriasis Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subjects randomize receive least one dose investigational product Study 20021639 20021642 ( provide meet inclusion/exclusion criterion protocol ) Active guttate , erythrodermic , pustular psoriasis time screen visit Pregnant breastfeeding female Evidence skin condition time screen visit ( e.g. , eczema ) would interfere evaluation effect investigational product psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Psoriasis , adult , skin</keyword>
	<keyword>Phase 3 , clinical trial</keyword>
	<keyword>Amgen , etanercept</keyword>
	<keyword>EnbrelÂ® , moderate</keyword>
	<keyword>severe , extension</keyword>
</DOC>